• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: BAYER PHARMA AG ESSURE; INSERT, TUBAL OCCLUSION

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

BAYER PHARMA AG ESSURE; INSERT, TUBAL OCCLUSION Back to Search Results
Model Number ESS305
Device Problem Insufficient Information (3190)
Patient Problems Abdominal Pain (1685); Fatigue (1849); Pain (1994); Thyroid Problems (2102); Tinnitus (2103); Visual Impairment (2138); Hot Flashes/Flushes (2153); Arthralgia (2355); Depression (2361); Heavier Menses (2666)
Event Date 06/07/2010
Event Type  Injury  
Event Description
This case was initially received via regulatory authority (b)(4) on (b)(6) 2017.This spontaneous case was reported by a consumer and describes the occurrence of abdominal pain lower ("low abdominal pain") and depression ("severe depression") in a (b)(6) -year-old female patient who had essure (batch no.700547) inserted.The occurrence of additional non-serious events is detailed below.On (b)(6) 2010, the patient had essure inserted.On the same day, the patient experienced abdominal pain lower (seriousness criterion medically significant), depression (seriousness criterion disability), hot flush ("enormous hot flushes"), arthralgia ("joint pain"), myalgia ("muscle pain"), eczema ("eczema"), fatigue ("enormous and persistent fatigue"), visual impairment ("important vision decrease"), tinnitus ("tinnitus"), tachycardia paroxysmal ("bout of tachycardia"), dyspnoea exertional ("breathless at the slightest effort") and hyperhidrosis ("excessive sweats in whole body leading to isolation").On an unknown date, the patient experienced disturbance in attention ("lack of concentration") and menorrhagia ("more abundant menstruations").The patient was treated with antidepressants.At the time of the report, the abdominal pain lower, depression, hot flush, arthralgia, myalgia, eczema, fatigue, visual impairment, tinnitus, tachycardia paroxysmal, dyspnoea exertional, hyperhidrosis, disturbance in attention and menorrhagia outcome was unknown.The reporter provided no causality assessment for abdominal pain lower, arthralgia, depression, disturbance in attention, dyspnoea exertional, eczema, fatigue, hot flush, hyperhidrosis, menorrhagia, myalgia, tachycardia paroxysmal, tinnitus and visual impairment with essure.The reporter commented: impossibility to work full time due to fatigue and antidepressive treatment (disability class 1).Diagnostic results (normal ranges are provided in parenthesis if available): body weight was reported to be (b)(6) kgs.Quality-safety evaluation of ptc: unable to confirm complaint.Most recent follow-up information incorporated above includes: on 9-oct-2017: quality-safety evaluation of ptc.The list of similar cases contains essure reports received by bayer and older cases received by conceptus with similar events coded in meddra.In this particular case a search in the database was performed on 10-oct-2017 for the following meddra preferred term: abdominal pain lower.The analysis in the global safety database revealed 577 cases.Bayer is closely monitoring the benefit-risk profile of essure.A recent cumulative review of all available data on essure has not yielded any new safety signal with regard to this meddra pt.Further company follow-up with the consumer or regulatory authority is not possible.Incident: at the time of reporting, there is no evidence that a device-related defect or malfunction caused a death or serious injury.If additional information becomes available it will be provided on a supplemental report.
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand Name
ESSURE
Type of Device
INSERT, TUBAL OCCLUSION
Manufacturer (Section D)
BAYER PHARMA AG
müllerstr. 178
berlin 13353
GM  13353
Manufacturer (Section G)
BAYER PHARMA AG
müllerstr. 178
berlin 13353
GM   13353
Manufacturer Contact
k. lamberson
100 bayer blvd.
p.o. box 915
whippany 07981-0915
MDR Report Key6979065
MDR Text Key90290190
Report Number2951250-2017-05454
Device Sequence Number1
Product Code HHS
Combination Product (y/n)N
Reporter Country CodeFR
PMA/PMN Number
P020014
Number of Events Reported1
Summary Report (Y/N)N
Report Source Manufacturer
Source Type consumer,foreign,other
Reporter Occupation Other
Type of Report Initial
Report Date 10/26/2017
1 Device was Involved in the Event
1 Patient was Involved in the Event
Is this an Adverse Event Report? Yes
Is this a Product Problem Report? No
Device Operator Health Professional
Device Model NumberESS305
Device Lot Number700547
Was Device Available for Evaluation? No
Was the Report Sent to FDA? No
Initial Date Manufacturer Received 09/26/2017
Initial Date FDA Received10/26/2017
Was Device Evaluated by Manufacturer? Device Not Returned to Manufacturer
Is the Device Single Use? Yes
Type of Device Usage Initial
Patient Sequence Number1
Patient Outcome(s) Other;
Patient Age51 YR
Patient Weight85
-
-